Longeveron Inc.
Healthcare / Biotechnology
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Performance
--
Today 0.00 (0.00%)
LGVN
Metrics
Market Cap21M
Latest Price$6.68
Previous Close$6.86
Volume232K
52 Week High$12.30
52 Week Low$4.75
52 Week Change-10.91%
Average Volume47K
Revenue1.2M
EPS-9.74
P/E Ratio0
Forward P/E-4.366
Price/Book2.037
Profit Margin0.00%
Operating Margin-21.50%
Return on Equity-2.04%
Dividend Yield0.00%